OncoZenge: Binding partnership agreement - Redeye

Redeye leaves a comment following OncoZenge’s announcement of having finalized a binding partnership agreement with specialty pharmaceutical company Molteni Farmaceutici for the commercialization of BupiZenge in Europe. We are encouraged to see that OncoZenge has managed secure an essential breakthrough in its journey of bringing BupiZenge to the market.

Länk till analysen i sin helhet: https://www.redeye.se/research/1091467/oncozenge-binding-partnership-agreement?utm_source=finwire&utm_medium=RSS